ReviewHepatology international2024
The contribution of genetics and epigenetics to MAFLD susceptibility.
Review in Hepatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 22 citations in OpenAlex.
- MASLD, diabetes and PMOS across the female life stages.Diabetologia · 2026Review
- Ultra-rapid progression of MAFLD to cirrhosis and post-transplant steatosis in a patient with a polygenic risk profile.MedScience · 2026Article
- Fibrosis and Perinatal Features Correlated with Telomere Shortening in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease.Life (Basel, Switzerland) · 2026Article
- Impact of Air Pollution on Metabolic Dysfunction-Associated Fatty Liver Disease.International journal of molecular sciences · 2026Review
- Distinct Roles of Myeloid- and Hepatocyte-PLA2G6 Deletion in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options.Molecular biomedicine · 2026Review
- The role of hepatocyte epigenetics in the pathogenesis of metabolic dysfunction-associated steatotic liver disease.Communications medicine · 2026Review
- Electroacupuncture activates the TET1/PPARα pathway to protect mitochondrial function in MASLD.Journal of inflammation (London, England) · 2026Article
- MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Efficacy and safety of lower-carbohydrate dietary patterns for metabolic associated fatty liver disease: evidence from randomized controlled trials with grade analysis.Nutrition & metabolism · 2026Article
- Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults.BMJ medicine · 2026Review
- Gut Microbiota-Derived Propionic Acid Mediates ApoA-I-Induced Amelioration of MASLD via Activation of GPR43-CaInternational journal of molecular sciences · 2026Article
- Cumulative Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: Findings from the Kailuan Cohort.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17.Frontiers in pharmacology · 2026Article
- Epigenetic signatures and cellular stress response pathways in metabolic dysfunction-associated steatotic liver disease: a personalized medicine perspective.Frontiers in physiology · 2026Review
- Early-Life Nutritional Determinants of Pediatric MASLD.Nutrients · 2025Review
- Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism.Nature metabolism · 2025Review
- Review
- Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver Biomarkers.International journal of molecular sciences · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide. The risk of developing MAFLD varies among individuals, due to a combination of environmental inherited and acquired genetic factors. Genome-wide association and next-generation sequencing studies are leading to the discovery of the common and rare genetic determinants of MAFLD. Thanks to the great advances in genomic technologies and bioinformatics analysis, genetic and epigenetic factors involved in the disease can be used to develop genetic risk scores specific for liver-related complications, which can improve risk stratification. Genetic and epigenetic factors lead to the identification of specific sub-phenotypes of MAFLD, and predict the individual response to a pharmacological therapy. Moreover, the variant transcripts and protein themselves represent new therapeutic targets. This review will discuss the current status of research into genetic as well as epigenetic modifiers of MAFLD development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.